Clinical Trial Update: Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer [Phase 2]

View source ↗

Summary

The Phase 2 trial of olaparib for recurrent BRCA-deficient ovarian cancer has been withdrawn (also related peritoneal and fallopian tube cancers).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Lynparza (olaparib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Ovarian Cancer, Peritoneal Cancer | Phase 2 | Status: WITHDRAWN